If at first you don't succeed a review of the evidence for antidepressant augmentation, combination and switching strategies

Drugs

Volumn 71, Issue 1, 2011, Pages 43-64

  Connolly, K Ryan ^a   Thase, Michael E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MIANSERIN; MIRTAZAPINE; MODAFINIL; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PINDOLOL; PLACEBO; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AKATHISIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; NEUROTRANSMITTER RELEASE; OUTCOME ASSESSMENT; REMISSION; RESTLESSNESS; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78650841139     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11587620-000000000-00000     Document Type: Review

References (84)

1. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995; 52: 1048-60.
2. Narasimhan M, Raynor JD, Jones AB. Depression in the medically ill: diagnostic and therapeutic implications. Curr Psychiatry Rep 2008; 10: 272-9.
3. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-59.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al., STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-42.
5. Tranter R, O'Donovan C, Chandarana P, et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002; 27: 241-7.
6. American Psychiatric Association practice guideline for treatment of patients with major depressive disorder, third edition [online]. Available from URL: http://www.psy chiatryonline.com/pracGuide/pracGuideTopic-7.aspx [Accessed 2010 Feb 26].
7. Malhi GS, Adams D, Porter R, et al., Northern Sydney Central Coast Mental Health Drug & Alcohol, NSW Health Clinical Redesign Program, CADE Clinic, University of Sydney. Clinical practice recommendations for depression. Acta Psychiatr Scand Suppl 2009; 119 (439): 8-26.
8. Lam RW, Kennedy SH, Grigoriadis S, et al., Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III: pharmacotherapy. J Affect Disord 2009; 117 Suppl. 1: S26-43
9. Institute for Clinical Systems Improvement (ICSI) healthcare guideline for major depression in adults in primary care [online]. Available from URL: http://www.icsi.org/ guidelines-and-more/gl-os-prot/behavioral-health/depres sion-5/depression-major-in-adults-in-primary-care-4. html [Accessed 2010 Feb 26].
10. Zall H, Therman PG, Myers JM. Lithium carbonate: a clinical study. Am J Psychiatry 1968; 125: 549-55.
11. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-34.
12. De Montigny C, Cournoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression: correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry 1983; 40: 1327-34.
13. Bschor T, Lewitzka U, Sasse J, et al. Lithium augmentation in treatment-resistant depression: clinical evidence, sero-tonergic and endocrine mechanisms. Pharmacopsychiatry 2003; 36 Suppl. 3: S230-4.
14. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68: 935-40.
15. Stein G, Bernadt M. Lithium augmentation therapy in tri-cyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162: 634-40.
16. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003; 23: 92-5.
17. Baumann P, Nil R, Souche A, et al. A double-blind, place-bo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-14.
18. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151: 1372-4.
19. Delgado PL, Price LH, Charney DS, et al. Efficacy of flu-voxamine in treatment-refractory depression. J Affect Disord 1988; 15: 55-60.
20. Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991; 83: 188-92.
21. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1519-30.
22. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53: 842-8.
23. Joffe RT, Sokolov ST, Levitt AJ. Lithium and triiodothyr-onine augmentation of antidepressants. Can J Psychiatry 2006; 51: 791-3.
24. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid sup-plementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617-22.
25. Prange Jr AJ, Wilson IC, Rabon AM, et al. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969; 126: 457-69.
26. Cooper-Kazaz R, Lerer B. Efficacy and safety of triio-dothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008; 11: 685-99.
27. Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679-88.
28. Papakostas GI, Shelton RC. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Curr Psychiatry Rep 2008; 10: 481-6.
29. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007; 68: 826-31.
30. Nemeroff CB. Use of atypical antipsychotics in refractory de-pression and anxiety. J Clin Psychiatry 2005; 66 Suppl. 8: 13-21.
31. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with anti-psychotics ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19 (7): 520-32.
32. Shelton RC, Tollefson GD, Tohen M, et al. A novel aug-mentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-4.
33. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/ fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66: 1289-97.
34. Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364-72.
35. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68: 224-36.
36. Bauer M, Pretorius HW, Constant EL, et al. Extended-re-lease quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70: 540-9.
37. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release que-tiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multi-centre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917-32.
38. Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008; 23: 269-75.
39. Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008; 8: 73.
40. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147: 593-602.
41. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43: 205-14.
42. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31: 2505-13.
43. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasi-done augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 217-21.
44. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68: 1071-7.
45. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843-53.
46. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psycho-pharmacol 2008; 28: 156-65.
47. Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry 2008; 10: 440-7.
48. Berman RM, Fava M, Thase ME, et al. Aripiprazole aug-mentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197-206.
49. Redrobe JP, Bourin M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psycho-pharmacology (Berl) 1998; 138: 198-206.
50. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998; 59: 664-8.
51. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448-52.
52. Trivedi MH, Fava M, Wisniewski SR, et al., STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-52.
53. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165: 342-51.
54. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004; 79: 137-47.
55. Brunton LB, Lazo JS, Parker KL, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2005.
56. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; (2): CD006722.
57. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006; 26: 653-6.
58. Ravindran AV, Kennedy SH, O'Donovan MC, et al. Os-motic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008; 69: 87-94.
59. Minzenberg MJ, Carter CS. Modafinil: a review of neuro-chemical actions and effects on cognition. Neuropsycho-pharmacology 2008; 33: 1477-502.
60. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial re-sponders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66: 85-93.
61. DeBattista C, Doghramji K, Menza MA, et al., Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1057-64.
62. Fava M, Thase ME, DeBattista C, et al. Modafinil aug-mentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007; 19: 153-9.
63. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine ex-tended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005; 22: 68-76.
64. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234-41.
65. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63: 424-34.
66. Bauer M, Tharmanathan P, Volz HP, et al. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009; 259: 172-85.
67. Poirier MF, Boyer P. Venlafaxine and paroxetine in treat-ment-resistant depression: double-blind, randomised comparison. Br J Psychiatry 1999; 175: 12-6.
68. Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psy-chopharmacol 2008; 23: 113-9.
69. Perahia DG, Quail D, Desaiah D, et al. Switching to du-loxetine in selective serotonin reuptake inhibitor non-and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009 Feb; 43 (5): 512-8.
70. Schatzberg AF. Pharmacological principles of antidepressant efficacy. Hum Psychopharmacol 2002; 17 Suppl. 1: S17-22.
71. Thase ME, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI non-response [abstract]. The Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health; 2001 May 28-31; Phoenix (AZ).
72. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163: 1161-72.
73. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mian-serin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psy-chiatr Scand 2001; 103: 66-72.
74. Nierenberg AA, Papakostas GI, Petersen T, et al. Nor-triptyline for treatment-resistant depression. J Clin Psychiatry 2003; 64: 35-9.
75. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233-9.
76. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 2007; 68 Suppl. 8: 35-41.
77. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987; 23: 169-72.
78. Thase ME, Frank E, Mallinger AG, et al. Treatment of imip-ramine- resistant recurrent depression, III: efficacy of mono-amine oxidase inhibitors. J Clin Psychiatry 1992; 53: 5-11.
79. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006 Sep; 163 (9): 1531-41; quiz 1666.
80. Carpenter LL, Yasmin S, Price LH. A double-blind, place-bo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51: 183-8.
81. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and par-oxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19: 457-65.
82. Blier P, Ward HE, Tremblay P, et al. Combination of anti-depressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-8.
83. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mian-serin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999; 19: 177-82.
84. Nelson JC, Mazure CM, Jatlow PI, et al. Combining nor-epinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004; 55: 296-300